Payment overview · 2025
General Payments
$1,991.70
99 reported records · 19 companies
Healthcare provider profile · identity verified
Harigopal Balaji, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLEVELAND, OH · NPI 1396730263
Verified facts
What the public records show
CMS Open Payments records show Harigopal Balaji, MD received $1,991.70 in general payments during 2025 across 99 reported records.
Vanda Pharmaceuticals Inc. accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brilinta, Eliquis, Fanapt, Farxiga, Jardiance, Ozempic, Trelegy Ellipta, Vraylar, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1229 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1229 claims for Eliquis by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $349.59 | 17.6% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $262.07 | 13.2% | 13 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $186.01 | 9.3% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $171.28 | 8.6% | 9 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $135.31 | 6.8% | 9 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $94.95 | 4.8% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $91.03 | 4.6% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $90.28 | 4.5% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $86.74 | 4.4% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $86.02 | 4.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $82.62 | 4.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.06 | 3.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.70 | 3.0% | 3 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $49.56 | 2.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.86 | 2.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $41.33 | 2.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $39.43 | 2.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.05 | 1.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.81 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,879.43 | 96 |
| Education | $112.27 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $349.59 | 16 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $227.18 | 11 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $186.01 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $135.89 | 6 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $135.31 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $128.82 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $125.11 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $90.28 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $84.08 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $82.62 | 5 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $77.18 | 4 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $67.66 | 3 | 2025 |
Source payment records
|
|||||
| QSYMIA Normalized: qsymia |
Drug | VIVUS LLC | $49.56 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $41.33 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $39.43 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $38.78 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $37.86 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.80 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $34.05 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRILINTA brilinta |
2025 | Brilinta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1229 | exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 123 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 230 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 244 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 127 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
123 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1229 | 138 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
127 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
230 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
183 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
244 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
45 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1229 | 138 |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2642 | 415 |
| Amlodipine Besylate | Amlodipine Besylate | 1963 | 330 |
| Furosemide | Furosemide | 1293 | 174 |
| Eliquis | Apixaban | 1229 | 138 |
| Gabapentin | Gabapentin | 1124 | 195 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1102 | 174 |
| Losartan Potassium | Losartan Potassium | 956 | 184 |
| Levothyroxine Sodium | Levothyroxine Sodium | 950 | 151 |
| Metoprolol Succinate | Metoprolol Succinate | 801 | 139 |
| Metoprolol Tartrate | Metoprolol Tartrate | 757 | 124 |
| Potassium Chloride | Potassium Chloride | 755 | 138 |
| Lisinopril | Lisinopril | 734 | 116 |
| Trazodone Hcl | Trazodone Hcl | 674 | 124 |
| Hydralazine Hcl | Hydralazine Hcl | 645 | 111 |
| Carvedilol | Carvedilol | 582 | 95 |
| Clopidogrel | Clopidogrel Bisulfate | 551 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 548 | 93 |
| Mirtazapine | Mirtazapine | 546 | 92 |
| Metformin Hcl | Metformin Hcl | 529 | 96 |
| Omeprazole | Omeprazole | 519 | 102 |
| Donepezil Hcl | Donepezil Hcl | 496 | 64 |
| Sertraline Hcl | Sertraline Hcl | 460 | 71 |
| Allopurinol | Allopurinol | 437 | 78 |
| Levetiracetam | Levetiracetam | 407 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 357 | 76 |
| Escitalopram Oxalate | Escitalopram Oxalate | 354 | 58 |
| Buspirone Hcl | Buspirone Hcl | 344 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 343 | 100 |
| Duloxetine Hcl | Duloxetine Hcl | 311 | 48 |
| Torsemide | Torsemide | 310 | 57 |
| Memantine Hcl | Memantine Hcl | 305 | 43 |
| Divalproex Sodium | Divalproex Sodium | 282 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 282 | 55 |
| Quetiapine Fumarate | Quetiapine Fumarate | 273 | 55 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 269 | 59 |
| Spironolactone | Spironolactone | 268 | 50 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 264 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 256 | 42 |
| Ozempic | Semaglutide | 244 | 35 |
| Januvia | Sitagliptin Phosphate | 243 | 40 |
| Jardiance | Empagliflozin | 230 | 26 |
| Xarelto | Rivaroxaban | 204 | 25 |
| Metformin Hcl Er | Metformin Hcl | 196 | 43 |
| Clonidine Hcl | Clonidine Hcl | 195 | 36 |
| Famotidine | Famotidine | 193 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 187 | 26 |
| Entresto | Sacubitril/Valsartan | 183 | 29 |
| Prednisone | Prednisone | 181 | 62 |
| Amiodarone Hcl | Amiodarone Hcl | 179 | 24 |
| Simvastatin | Simvastatin | 177 | 35 |
| Warfarin Sodium | Warfarin Sodium | 164 | 22 |
| Baclofen | Baclofen | 155 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 155 | 63 |
| Latanoprost | Latanoprost | 153 | 32 |
| Doxazosin Mesylate | Doxazosin Mesylate | 147 | 22 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 144 | 39 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 137 | 15 |
| Nifedipine Er | Nifedipine | 130 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 130 | 32 |
| Glimepiride | Glimepiride | 129 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 127 | 30 |
| Farxiga | Dapagliflozin Propanediol | 123 | 25 |
| Bupropion Xl | Bupropion Hcl | 121 | 17 |
| Finasteride | Finasteride | 120 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 51 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 112 | 31 |
| Atenolol | Atenolol | 110 | 17 |
| Tramadol Hcl | Tramadol Hcl | 107 | 44 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 106 | 21 |
| Aripiprazole | Aripiprazole | 105 | 23 |
| Ezetimibe | Ezetimibe | 100 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 99 | 19 |
| Meloxicam | Meloxicam | 97 | 26 |
| Olanzapine | Olanzapine | 97 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 95 | 48 |
| Montelukast Sodium | Montelukast Sodium | 93 | 22 |
| Risperidone | Risperidone | 92 | 17 |
| Midodrine Hcl | Midodrine Hcl | 89 | 27 |
| Sucralfate | Sucralfate | 85 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 84 | 64 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 82 | 15 |
| Sevelamer Carbonate | Sevelamer Carbonate | 81 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 80 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 80 | 24 |
| Alprazolam | Alprazolam | 79 | 22 |
| Humalog Kwikpen U-100 | Insulin Lispro | 78 | 24 |
| Albuterol Sulfate | Albuterol Sulfate | 77 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 53 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 76 | 30 |
| Valsartan | Valsartan | 76 | suppressed |
| Glipizide | Glipizide | 75 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 75 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 75 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | 27 |
| Nystatin | Nystatin | 72 | 27 |
| Meclizine Hcl | Meclizine Hcl | 71 | 25 |
| Pregabalin | Pregabalin | 70 | 25 |
| Ibuprofen | Ibuprofen | 68 | 19 |
| Ketoconazole | Ketoconazole | 68 | 31 |
| Metoclopramide Hcl | Metoclopramide Hcl | 67 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 14 |
| Azithromycin | Azithromycin | 63 | 53 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 13 |
| Myrbetriq | Mirabegron | 60 | suppressed |
| Ampicillin-Sulbactam | Ampicillin Sod/Sulbactam Sod | 59 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 59 | suppressed |
| Lidocaine | Lidocaine | 59 | 14 |
| Alendronate Sodium | Alendronate Sodium | 58 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 56 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 56 | 19 |
| Ceftriaxone | Ceftriaxone Sodium | 55 | 25 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 54 | suppressed |
| Ranolazine Er | Ranolazine | 54 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 53 | 14 |
| Digoxin | Digoxin | 53 | suppressed |
| Glipizide Er | Glipizide | 53 | 13 |
| Topiramate | Topiramate | 53 | suppressed |
| Trulicity | Dulaglutide | 53 | 11 |
| Cephalexin | Cephalexin | 52 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 12 |
| Lamotrigine | Lamotrigine | 50 | suppressed |
| Lorazepam | Lorazepam | 50 | 22 |
| Amoxicillin | Amoxicillin | 49 | 35 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 22 |
| Sodium Chloride | 0.9 % Sodium Chloride | 48 | 21 |
| Procrit | Epoetin Alfa | 47 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 45 | 43 |
| Acyclovir | Acyclovir | 43 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 42 | suppressed |
| Brilinta | Ticagrelor | 40 | suppressed |
| Epogen | Epoetin Alfa | 40 | suppressed |
| Haloperidol | Haloperidol | 40 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 39 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 39 | suppressed |
| Fluconazole | Fluconazole | 39 | 27 |
| Humalog | Insulin Lispro | 38 | 16 |
| Nitroglycerin | Nitroglycerin | 38 | 22 |
| Carbamazepine Er | Carbamazepine | 37 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | 11 |
| Levofloxacin | Levofloxacin | 36 | 23 |
| Linzess | Linaclotide | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | 13 |
| Lacosamide | Lacosamide | 35 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 34 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 34 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 34 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | 18 |
| Lovastatin | Lovastatin | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Ethacrynic Acid | Ethacrynic Acid | 32 | suppressed |
| Nyamyc | Nystatin | 32 | 16 |
| Prednisolone Acetate | Prednisolone Acetate | 32 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | suppressed |
| Calcium Acetate | Calcium Acetate | 31 | suppressed |
| Colchicine | Colchicine | 31 | 13 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 31 | suppressed |
| Creon | Lipase/Protease/Amylase | 30 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | 12 |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 28 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 27 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 27 | 11 |
| Novolog Flexpen | Insulin Aspart | 27 | 11 |
| Permethrin | Permethrin | 27 | 22 |
| Restasis | Cyclosporine | 27 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Daptomycin | Daptomycin | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Ingrezza | Valbenazine Tosylate | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Zonisamide | Zonisamide | 26 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 25 | suppressed |
| Timolol Maleate | Timolol Maleate | 25 | 11 |
| Amiloride Hcl | Amiloride Hcl | 24 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 12 |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | 15 |
| Dexamethasone | Dexamethasone | 22 | 17 |
| Dilt-Xr | Diltiazem Hcl | 22 | suppressed |
| Fycompa | Perampanel | 22 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 22 | suppressed |
| Insulin Lispro | Insulin Lispro | 22 | 13 |
| Methimazole | Methimazole | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 21 | suppressed |
| Budesonide | Budesonide | 21 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 21 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 21 | 13 |
| Metolazone | Metolazone | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 13 |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 20 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Tivicay | Dolutegravir Sodium | 19 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 18 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 17 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 17 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | 12 |
| Austedo | Deutetrabenazine | 16 | suppressed |
| Enulose | Lactulose | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Tobramycin | Tobramycin | 14 | suppressed |
| Admelog | Insulin Lispro | 13 | suppressed |
| Alphagan P | Brimonidine Tartrate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 13 | 12 |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Fanapt | Iloperidone | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Meropenem | Meropenem | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,991.70 · 99 records | Vanda Pharmaceuticals Inc. | AFREZZA, AIRSUPRA, AREXVY, BREZTRI, BRILINTA, CAMZYOS, COBENFY, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FANAPT, FARXIGA, GVOKE HYPOPEN, HETLIOZ, JARDIANCE, Kerendia, LEQVIO, NURTEC ODT, Ozempic, PAXLOVID, QSYMIA, QULIPTA, RECORLEV, REXULTI, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VRAYLAR, VYNDAMAX, ZAVZPRET, ZENPEP | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brilinta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error